Open access
Open access
Powered by Google Translator Translator

Hematology (all articles)

Clinical Cancer Advances 2021: ASCO’s Report on Progress Against Cancer

7 Feb, 2021 | 20:45h | UTC

Clinical Cancer Advances 2021: ASCO’s Report on Progress Against Cancer – Journal of Clinical Oncology

Commentary: ASCO Names Molecular Profiling in GI Cancers as Advance of the Year – OncLive

 


ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

3 Feb, 2021 | 01:07h | UTC

ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease – Blood

 


[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials

1 Feb, 2021 | 01:58h | UTC

Full-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)

Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial

News release: Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients – National Institutes of Health

 


Preliminary study shows sitagliptin may prevent acute Graft-versus-Host Disease

26 Jan, 2021 | 00:35h | UTC

Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Sitagliptin promising addition for preventing acute GVHD – HealthDay

 


Cohort study: Long-term clinical outcomes of hematopoietic stem cell transplantation in 210 patients with multiple sclerosis

25 Jan, 2021 | 01:15h | UTC

Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis – Neurology (link to abstract – $ for full-text)

 


[Press Release – Not Published Yet] Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients

25 Jan, 2021 | 01:42h | UTC

Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients – National Institutes of Health

 


Cohort study: Recipients of hematopoietic stem-cell transplantation who develop COVID-19 have poor overall survival

21 Jan, 2021 | 01:18h | UTC

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study – The Lancet Haematology

 


Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb

21 Jan, 2021 | 01:10h | UTC

Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb – Cochrane Library

Summary: Thrombolysis for treatment of acute deep vein thrombosis – Cochrane Library

 


Meta-Analysis: Low-intensity warfarin may be an option for patients under 65 years of age with non-valvular atrial fibrillation

21 Jan, 2021 | 00:57h | UTC

Meta-Analysis Evaluating the Efficacy and Safety of Low-Intensity Warfarin for Patients >65 Years of Age With Non-Valvular Atrial Fibrillation – The American Journal of Cardiology (link to abstract – $ for full-text)

 


[Abstract Only] Meta-analysis: Myelodysplastic syndrome and acute myeloid leukemia in patients treated with PARP inhibitors

21 Jan, 2021 | 00:37h | UTC

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database – The Lancet Haematology (link to abstract – $ for full-text)

Commentary: PARP Inhibitors Linked With Blood Cancer Risk — Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden – MedPage Today

 

Commentary on Twitter

 


Randomized trial: Dabigatran non-inferior to standard of care for children with acute venous thromboembolism

21 Jan, 2021 | 00:35h | UTC

Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial – The Lancet Haematology (link to abstract – $ for full-text)

 


RECOVERY trial: No Benefit from convalescent plasma in hospitalized patients with Covid-19

17 Jan, 2021 | 22:26h | UTC

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

Commentary: Covid: ‘Convalescent plasma no benefit to hospital patients’ – BBC

 


Observational study: Among patients hospitalized with Covid-19 not receiving mechanical ventilation, transfusion of plasma with higher anti–SARS-CoV-2 IgG antibody levels is linked to lower risk of death than transfusion of plasma with lower antibody levels

15 Jan, 2021 | 08:59h | UTC

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19 – New England Journal of Medicine

Editorial: (A Little) Clarity on Convalescent Plasma for Covid-19 – New England Journal of Medicine

Commentaries: Expert reaction to study looking at convalescent plasma antibody levels and risk of death from COVID-19 – Science Media Centre AND Antibody-rich convalescent plasma may lower risk of COVID death – CIDRAP

 


Opinion: RCTs don’t justify using convalescent plasma or antibody cocktails

15 Jan, 2021 | 08:58h | UTC

RCTs don’t justify using convalescent plasma or antibody cocktails – PulmCrit

 


Randomized trial: Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma

15 Jan, 2021 | 08:12h | UTC

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Triplet therapy slows refractory multiple myeloma – MedicalXpress

 


Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

13 Jan, 2021 | 01:37h | UTC

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy – Cochrane Library

Summary: Prevention of blood clots in non-hospitalised cancer patients receiving chemotherapy – Cochrane Library

 


Blood plasma treatment has limited effect for sickest COVID-19 patients

12 Jan, 2021 | 02:07h | UTC

Blood plasma treatment has limited effect for sickest COVID-19 patients – Imperial College London

See also: Expert reaction to REMAP-CAP recruitment of severely ill COVID-19 patients into convalescent plasma trial being paused after initial analysis suggested it did not improve outcomes – Science Media Centre AND Trial of COVID-19 blood plasma finds no benefit in severely ill patients – Reuters

 


Randomized trial: Plasma therapy administered early is beneficial in high-risk elderly patients

12 Jan, 2021 | 02:05h | UTC

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults – New England Journal of Medicine

Commentaries: Early convalescent plasma may lower risk of severe COVID in seniors – CIDRAP AND Covid-19: Early Plasma Treatment Improved Outcomes in Older Patients – Physician’s Weekly

 

Commentaries on Twitter

 


ACC Consensus: Anticoagulation and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing PCI or with atherosclerotic cardiovascular disease

12 Jan, 2021 | 01:50h | UTC

2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee – Journal of the American College of Cardiology

Commentaries: ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE – TCTMD AND ACC Issues Clinical Guidance For Antithrombotic Therapy in Patients With AFib or VTE Undergoing PCI or With ASCVD – American College of Cardiology

 

Commentary on Twitter

 


[Press release – results not published yet] International trials of blood thinners in critically ill COVID-19 patients pause due to futility

10 Jan, 2021 | 20:44h | UTC

International trials of blood thinners in critically ill COVID-19 patients pause due to futility – NIH News Releases

 

Commentary on Twitter

 


Randomized trial: In extremely-low-birth-weight infants, a higher hemoglobin threshold for red-cell transfusion does not improve outcomes

10 Jan, 2021 | 20:36h | UTC

Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Higher red cell transfusion threshold offers no advantage for treating preterm infants – NIH News Releases

 


Case series: Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer

2 Dec, 2020 | 07:31h | UTC

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer – New England Journal of Medicine

 


NICE COVID-19 guideline: Prevention of thromboembolism in patients with COVID-19. “For patients who are having advanced respiratory support: consider increasing pharmacological VTE prophylaxis to an intermediate dose”

1 Dec, 2020 | 08:19h | UTC

COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19 – National Institute for Health and Care Excellence

 


Randomized trial: Intravenous iron is superior to oral iron for the treatment of anemia in women after childbirth in a low-income setting

27 Nov, 2020 | 08:41h | UTC

Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial – The Lancet Global Health

Commentary: Iron infusion highly effective to treat anemia in low-income settings – Swiss Tropical and Public Health Institute / News Medical

 

Commentary on Twitter

 


Randomized trial: Convalescent Plasma does not improve clinical status or overall mortality in severe Covid-19 pneumonia

25 Nov, 2020 | 09:17h | UTC

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia – New England Journal of Medicine

Commentary: New trial of convalescent plasma for covid-19 falls flat, another setback for hyped treatment – Brief19

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.